Premium
Effects of ABT‐229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro‐oesophageal reflux disease
Author(s) -
Netzer P.,
Schmitt B.,
Inauen W.
Publication year - 2002
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2002.01324.x
Subject(s) - gastric emptying , reflux , gastroenterology , medicine , placebo , gastro , motilin , breath test , gastric acid , stomach , helicobacter pylori , disease , pathology , alternative medicine
Summary Aim : The effect of ABT‐229, a new macrolide with no antibacterial activity, on gastro‐oesophageal reflux, oesophageal motility and gastric emptying in patients with gastro‐oesophageal reflux disease was investigated. Methods : Twenty‐one patients were treated with a placebo and ABT‐229 (2.5, 5 or 10 mg b.d.) in a randomized, incomplete crossover study design. Ambulatory 24‐h pH manometry was performed and gastric emptying was assessed by the 13 C‐octanoic acid breath test on the seventh day of treatment. Results : A significant decrease was found in the mean (± s.e.) percentage of reflux time (intra‐oesophageal pH < 4) for ABT‐229 5 mg b.d. and 10 mg b.d., but not for 2.5 mg b.d., compared with placebo. For ABT‐229 5 mg, it was 8.5 ± 0.5% vs. 10.7 ± 0.7% ( P < 0.038) and, for ABT‐229 10 mg, it was 6.6 ± 0.5% vs. 8.4 ± 0.5% ( P < 0.019). There were no significant differences in any of the analysed manometric parameters. In addition, the gastric half‐emptying time for all doses of ABT‐229 did not differ significantly from that after placebo. Conclusions : ABT‐229 is able to reduce slightly, but significantly, acid reflux in patients with gastro‐oesophageal reflux disease. This effect does not appear to be due to a measurable improvement in oesophageal motility or gastric emptying.